
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics has demonstrated strong commercial execution, particularly with the easing of Risk Evaluation and Mitigation Strategy (REMS) requirements, which is anticipated to enhance prescriber adoption of its product FILSPARI. The acceleration of sparsentan sales and progress in the Japanese regulatory pathway solidify its potential as a foundational therapy for IgA nephropathy, strengthening the company's position in a competitive market. Additionally, the cancellation of the Advisory Committee meeting and the favorable stock response underscore positive developments that could further benefit Travere’s market standing and financial performance.
Bears say
The negative outlook on Travere Therapeutics's stock is informed by significant uncertainties regarding its clinical trial outcomes, which may jeopardize the progression of its therapeutic candidates through development. Additionally, recent FDA actions, including leadership changes and shifting review practices, have created an environment of increased scrutiny in the biotech sector, heightening investor apprehension. Furthermore, the company could face challenges in securing adequate funding necessary to support its drug development initiatives, compounding the risks associated with its ongoing projects.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares